Matilde Pensabene

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

Journal: Clinical breast cancer

Published: April 22, 2026

Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer.

Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer.

Journal: PloS one

Published: August 05, 2024

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.

Journal: Cancer treatment reviews

Published: February 06, 2024

Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.

Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.

Journal: Cancer treatment reviews

Published: December 30, 2023

Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.

Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.

Journal: Future oncology (London, England)

Published: August 22, 2023

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.

Journal: Frontiers in oncology

Published: April 30, 2023

Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy.

Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy.

Journal: Frontiers in medicine

Published: March 11, 2022

Male Breast Cancer: From Molecular Genetics to Clinical Management.

Male Breast Cancer: From Molecular Genetics to Clinical Management.

Journal: Cancers

Published: March 05, 2022

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.

Journal: Journal of translational medicine

Published: March 08, 2021

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.

Journal: International journal of molecular sciences

Published: July 31, 2020

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

Journal: International journal of molecular sciences

Published: July 20, 2020

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Journal: Diagnostics (Basel, Switzerland)

Published: August 08, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026